Welcome to our dedicated page for Endo International plc news (Ticker: ENDP), a resource for investors and traders seeking the latest updates and insights on Endo International plc stock.
Endo International plc (OTC: ENDPQ) is a leading specialty pharmaceutical company dedicated to improving the lives of patients through innovative and high-quality therapies. With a global team of passionate professionals, Endo transforms insights into effective treatments and ensures these are available to those who need them most.
Endo's core business revolves around the development, manufacturing, and marketing of branded and generic pharmaceutical products. The company focuses on areas such as pain management, urology, endocrinology, and oncology, catering to various unmet medical needs. Over the years, Endo has built a robust portfolio of products that enhance the quality of life for patients worldwide.
Recent Achievements and Projects:
- On September 21, 2023, Endo announced the presentation of data from clinical studies of collagenase clostridium histolyticum (CCH) for treating plantar fibromatosis at the American Orthopaedic Foot & Ankle Society's annual meeting. These studies showed improvement in nodule hardness and patient satisfaction, with a consistent safety profile.
- Endo has completed a Phase 2 study of CCH and anticipates beginning the pivotal Phase 3 program later this year. This effort underscores Endo's commitment to developing nonsurgical treatment options for conditions like plantar fibromatosis.
Endo's financial condition is currently under strategic restructuring, including Chapter 11 proceedings, aimed at addressing the company's liabilities and ensuring long-term viability. Despite these challenges, Endo continues to prioritize its mission of delivering life-enhancing therapies.
Endo's partnerships and collaborations play a crucial role in its success. By working with healthcare professionals, research institutions, and other industry stakeholders, Endo stays at the forefront of pharmaceutical innovation and effectively meets market demands.
For more information about Endo and its latest news, visit www.endo.com or connect with the company on LinkedIn.
Endo International plc (NASDAQ: ENDP) announced a settlement in principle for the Staubus opioid-related case in Tennessee, agreeing to pay a total of $35 million to resolve claims from nine counties and multiple cities involving opioid litigation. The settlement must be finalized by certain plaintiffs and will not imply admission of wrongdoing by Endo. The trial, originally set for July 26, 2021, is postponed to August 2, 2021, to allow for necessary approvals. This agreement aims to fully resolve the case without further liability.
Endo International plc (NASDAQ: ENDP) announced on July 15, 2021, that the Tennessee Supreme Court has denied its requests regarding a default judgment order related to the Staubus case, alleging violations of Tennessee's Drug Dealer Liability Act. The Tennessee Court of Appeals also dismissed Endo's appeal. A trial for damages is scheduled for July 26, 2021. Endo maintains that the default judgment is unjustified and is considering legal options. In December 2020, the Tennessee Supreme Court ruled that the District Attorneys General lack standing in such claims.
Endo International plc (NASDAQ: ENDP) will release its second-quarter 2021 financial results on August 5, 2021, after U.S. market close. A conference call is scheduled for August 6, 2021, at 7:30am ET. Investors can join via a U.S. dial-in number or through a webcast available on the company’s investor relations page. A replay will be accessible until August 16, 2021. This update highlights Endo's ongoing commitment to delivering quality therapies and provides essential dates for investors to monitor financial performance.
Endo International plc (NASDAQ: ENDP) announced the presentation of new data regarding Qwo® (collagenase clostridium histolyticum-aaes) for cellulite treatment at the Cosmetic Bootcamp Summer Event held from June 24-27, 2021, in Aspen, CO. The data includes findings from a Phase 4 trial on bruising mitigation and interim results of real-world effectiveness. Qwo, FDA-approved in July 2020 for moderate to severe cellulite in adult women, is contraindicated in patients with hypersensitivity to collagenase or with infections at injection sites. Safety precautions and adverse reactions are also detailed in the release.
Endo International plc (NASDAQ: ENDP) announced on June 11, 2021, that the Tennessee Court of Appeals addressed a default judgment against its subsidiaries, Endo Health Solutions Inc. and Endo Pharmaceuticals Inc., from April 2021. The court declined to review the judgment, affirming that Endo must pursue further actions to challenge it. Endo claims the judgment is procedurally flawed and plans to appeal to the Tennessee Supreme Court. The original case involved allegations of violating Tennessee's Drug Dealer Liability Act, with a trial for damages set for July 26, 2021.
Endo International plc (NASDAQ: ENDP) reported Q1 2021 financial results, showing total revenues of $718 million, a 12% decline year-over-year. The Branded Pharmaceuticals segment saw a slight revenue growth of 1%, primarily due to strong demand for XIAFLEX®. However, income from continuing operations dropped 70% to $47 million, with diluted net income per share also decreasing by 71% to $0.20. The company is updating its full-year financial guidance, reflecting uncertainties related to the COVID-19 pandemic.
Maverix Private Equity, a Toronto-based firm, has launched its inaugural USD $500 million growth fund and appointed Michael Wasserman as Managing Partner. Wasserman, a former Managing Director at H.I.G. Capital Management, will focus on healthcare investments. Additionally, Peter Hass has joined as Associate Partner, overseeing investment deal execution. Jonathan Goodman, co-founder of Paladin Labs, is joining the Maverix Advisory Board. Maverix targets North American companies with strong growth potential and a profitable business model, with average investments of USD $50 million.
Endo International plc (NASDAQ: ENDP) announced that data regarding Qwo® (collagenase clostridium histolyticum-aaes), FDA-approved for treating cellulite in adult women, will be showcased at The Aesthetic Meeting 2021 in Miami from April 29 to May 3, 2021. Key presentations include studies on reduction in dimple volume and interim analysis of safety and effectiveness for thigh cellulite. Qwo is contraindicated for those with hypersensitivity to collagenase and has reported adverse reactions such as bruising in 84% of subjects.
Endo International plc (NASDAQ: ENDP) announced the appointment of Mark Barberio as Chairman of the Board, effective at the 2021 Annual General Meeting. This change is a part of Endo's ongoing Board succession plan, which has already seen the addition of two new Board members. Paul Campanelli, outgoing Chairman, will retire alongside Roger Kimmel, Senior Independent Director. Barberio, who joined the Board in February 2020, aims to lead the company through its transformation while acknowledging the significant contributions of Campanelli and Kimmel.
Endo International plc (NASDAQ: ENDP) is set to announce its first-quarter 2021 financial results on May 6, 2021. A conference call will follow on May 7, 2021, at 7:30 AM ET, with access details provided for both U.S./Canada and international callers. A replay of the call will be available until May 17, 2021. Investors can access the call via phone or a simultaneous webcast, which will also be available on Endo's website for one year.
FAQ
What does Endo International plc do?
What recent achievements has Endo announced?
What are Endo's core therapeutic areas?
What is plantar fibromatosis?
What is Endo’s financial situation?
How is Endo addressing unmet medical needs?
Where can I find more information about Endo?
What is CCH and what is its significance?
Is CCH approved for treating plantar fibromatosis?
What partnerships does Endo engage in?
